Is Orforglipron legal in United Kingdom?

The MHRA authorised orforglipron (Foundayo, Eli Lilly) on 10 August 2026, the first authorisation in Europe. It is licensed for weight loss and weight maintenance in adults with a BMI of 30 or more, or 27 to 30 with at least one weight-related condition, and for type 2 diabetes that is not well controlled. It is prescription-only and was not available on the NHS when authorised; the MHRA said NHS use will follow an evaluation by NICE. In June 2026, before it was licensed, the MHRA, ASA and GPhC warned businesses that promoting pipeline weight-management medicines (including waiting lists) and newly licensed oral GLP-1s to the public is likely to break the advertising rules. The MHRA's additional monitoring list shows Foundayo tablets under UK product licences held by Eli Lilly.